{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:22:18Z","timestamp":1787851338080,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108311","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:11:51Z","timestamp":1784833911000},"page":"108311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Somatic BRCA alterations in breast cancer are associated with distinct biological and clinical patterns according to germline BRCA status"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1404-1570","authenticated-orcid":false,"given":"M.","family":"Oshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2503-9350","authenticated-orcid":false,"given":"K.","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-5167","authenticated-orcid":false,"given":"M.","family":"Sugimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-6250","authenticated-orcid":false,"given":"K.","family":"Onel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Takabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108311_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7314\/APJCP.2016.17.S3.43","article-title":"Incidence and mortality and epidemiology of breast cancer in the world","volume":"17","author":"Ghoncheh","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.esmoop.2026.108311_bib2","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108311_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D\u2019Andrea","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.esmoop.2026.108311_bib4","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108311_bib5","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108311_bib6","article-title":"Impact of BRCA mutation on treatment outcomes of endocrine therapy \u00b1 CDK4\/6 inhibitors in hormone receptor-positive\/human epidermal growth factor receptor-2-negative breast cancer: a systematic review and meta-analysis","volume":"9","author":"Azim","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108311_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","article-title":"A real-world evidence study of CDK4\/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status","volume":"9","author":"Collins","year":"2021","journal-title":"Oncol Ther"},{"key":"10.1016\/j.esmoop.2026.108311_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009058","article-title":"Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8(+) TILs based on BRCA1\/2 mutation status in epithelial ovarian cancers","volume":"12","author":"Park","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.108311_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108311_bib10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/biomedicines12030593","article-title":"Predictive value and therapeutic significance of somatic BRCA mutation in solid tumors","volume":"12","author":"Szentmartoni","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.esmoop.2026.108311_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108311_bib12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1200\/JCO-25-02075","article-title":"TBCRC 048 (olaparib expanded) expansion cohorts: phase II study of olaparib monotherapy for patients with metastatic breast cancer with germline mutations in PALB2 or somatic mutations in BRCA1 or BRCA2","volume":"44","author":"Tung","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108311_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-026-02305-9","article-title":"TP53 mutation is associated with shorter treatment duration with CDK4\/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive\/HER2-negative breast cancer: real-world perspective","author":"Oshi","year":"2026","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108311_bib14","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/j.1349-7006.2008.00944.x","article-title":"Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast\/ovarian cancer","volume":"99","author":"Sugano","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2026.108311_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975326","article-title":"BRCA1\/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients","volume":"12","author":"Incorvaia","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2026.108311_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/CLEP.S206949","article-title":"A systematic review of the international prevalence of BRCA mutation in breast cancer","volume":"11","author":"Armstrong","year":"2019","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.esmoop.2026.108311_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2021.10.002","article-title":"Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial","volume":"163","author":"Hodgson","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2026.108311_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oncolo\/oyac164","article-title":"Concordance between genomic alterations detected by tumor and germline sequencing: results from a tertiary care academic center molecular tumor board","volume":"28","author":"Green","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108311_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","article-title":"Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes","volume":"8","author":"Riaz","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108311_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-017-2459-z","article-title":"Next-generation sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations","volume":"133","author":"Balendran","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.esmoop.2026.108311_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231999","article-title":"The genomic landscape of metastatic breast cancer: insights from 11,000 tumors","volume":"15","author":"Rinaldi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.108311_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2018.11.016","article-title":"Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: deep sequencing data from ovarian cancer patients","volume":"152","author":"Kotoula","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2026.108311_bib23","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1245\/s10434-007-9372-1","article-title":"Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis","volume":"14","author":"King","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmoop.2026.108311_bib24","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","article-title":"Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment","volume":"21","author":"VanArsdale","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108311_bib25","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-21-2428","article-title":"Functional genomic analysis of CDK4 and CDK6 gene dependency across human cancer cell lines","volume":"82","author":"Zhang","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108311_bib26","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.4161\/cc.29082","article-title":"The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4\/6-RB axis","volume":"13","author":"Lou","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.esmoop.2026.108311_bib27","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/ijms21061960","article-title":"The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2026.108311_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/tbcr-25-46","article-title":"BRCA and CDK4\/6: allies or antagonists?-efficacy of CDK4\/6 inhibitors in HR(+)\/HER2(-) breast cancer with germline BRCA1\/2 mutations: a narrative review","volume":"7","author":"Illia","year":"2026","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108311_bib29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10549-018-05127-2","article-title":"BRCA1\/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients","volume":"174","author":"Friedlaender","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108311_bib30","doi-asserted-by":"crossref","first-page":"e1471","DOI":"10.1634\/theoncologist.2019-0272","article-title":"Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy","volume":"24","author":"Weitzner","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108311_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/igc.0000000000001144","article-title":"BRCA mutation status is not associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer","volume":"28","author":"Kotsopoulos","year":"2018","journal-title":"Int J Gynecol Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:35:10Z","timestamp":1787848510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926022532"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108311","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatic BRCA alterations in breast cancer are associated with distinct biological and clinical patterns according to germline BRCA status","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108311"}}